国际肿瘤学杂志 ›› 2019, Vol. 46 ›› Issue (10): 613-616.doi: 10.3760/cma.j.issn.1673-422X.2019.10.009

• 综述 • 上一篇    下一篇

Group3型髓母细胞瘤MYC抑制相关机制的研究

杨希林,陈晓品   

  1. 重庆医科大学附属第一医院肿瘤科400016

  • 出版日期:2019-10-08 发布日期:2019-12-20
  • 通讯作者: 陈晓品,Email: cxp640910@163.com E-mail:cxp640910@163.com

MYC inhibition associated mechanism research of Group3 medulloblastoma

Yang Xilin, Chen Xiaopin   

  1. Department of Oncology, First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China

  • Online:2019-10-08 Published:2019-12-20
  • Contact: Chen Xiaopin, Email: cxp640910@163.com E-mail:cxp640910@163.com

摘要:

髓母细胞瘤是儿童最好发的脑部肿瘤。Group3型是其中恶性程度最高的亚型,相当一部分基因表型呈MYC扩增。对MYC上游基因位点的阻断主要通过miR494DDX3NOTCH1通道实现;通过BETiATR/Chk1双抑制实现MYC复制转录的抑制;针对MYC下游基因的阻断则主要集中于LDHASETD8EZH2上。这些针对MYC扩增进行的一系列抗肿瘤治疗机制的研究,为临床抗MYC相关性髓母细胞瘤提供了理论依据。

关键词: 髓母细胞瘤, 基因, MYC, Group3, 治疗机制

Abstract: Medulloblastoma (MB) is the most prevalent pediatric brain tumor. Group3 MB is the most malignant subgroup, quiet a part of which are MYC-amplified. Blocking the upstream gene sites of MYC is mainly achieved through the blockade of miR-494, DDX3, NOTCH1 pathway; BETi or ATR/Chk1 double-inhibition realizes the inhibition of duplication or transcription of MYC; as to the blockade of downstream genes of MYC, researchers mainly focus on LDHA, SETD8 and EZH2. All of these researches which target on MYC-amplified associated anti-tumor treatment mechanism present the theoretical basis for anti-MYC-associated medulloblastoma clinically.

Key words: Medulloblastoma, Genes, MYC, Group3, Treatment mechanism